Colgate-Palmolive Company (CL) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Colgate-Palmolive Company stock $56.16, price $98.69, that is 43.1% below the price, quality 74 out of 100. Rating: strongly overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $61.87 – $103.20 · fair‑value band $40.06 – $70.20 · the $98.69 price screens above the $56.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Colgate-Palmolive in your weekly email
Every Wednesday you see whether Colgate-Palmolive is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition.
Show moreShow less
The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.
This segment markets and sells its products under the Colgate, Palmolive, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline, and Suavitel brands to a range of traditional and eCommerce retailers, wholesalers, and distributors, as well as dentists and skin health professionals.
It also offers pharmaceutical products for dentists and other oral health professionals.
The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic pet products to help nutritionally support dogs and cats in different stages of health under the Hill's Prescription Diet brand; and a fresh pet food sold to pet specialty and other retailers in Australia under Prime100 brand.
This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
Stock analysis
Colgate-Palmolive Company (CL) currently trades at $98.69, while our model-based Fair Value estimate is $56.16, 43% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $56.16 per share, and 0 of the 23 models we run sit above the $98.69 price.
Bear case: the Dividend Discount group reads lowest at $33.86, and 23 of the 23 models stay below the price. Data coverage for this calculation is high.
Scenario range: $40.06 (bear) to $70.20 (bull), the price of $98.69 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Consumer Defensive sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Colgate-Palmolive Company reported revenue of $20.4B in FY2025 versus $17.4B in FY2021, a compound +4.0%/yr. Reported net income was $2.1B in FY2025, compounding −0.4%/yr from FY2021.
Key figures
Market cap $79.5B Large · P/E ratio 38.9 · P/S ratio 3.78 · EPS (TTM) $2.54 · Dividend yield 2.1% · Net margin 9.7% · Return on equity 267% · Return on assets (EBIT) 25.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 80 out of 100 (medium confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades at its 52-week high and 33% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −25% fair-value upside, at −43%, CL screens richer than that median.
Fair Value models
Bear$40.06Fair Value $56.16Bull$70.20
Price $98.69 · Downside -43.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.3822 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Plus 34 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.72/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+1.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Start year 2020 (pandemic). Over 10 years: +2.4% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+5.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.6%
Dividend (yield on the price)2.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.9% vs 1.1%, steady
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 22%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +5.6% a year for the price and +0.9% for the forecasts.
AI conclusion: Global oral care strength and higher-margin pet nutrition deliver resilient demand, yet developed-market categories continue to weigh on results.
Main risk: New entrants offering microbiome-focused or novel-ingredient oral care products via direct-to-consumer models could erode Colgate-Palmolive's share in its core oral care portfolio and pressure pricing or margins.
Bull case: By accelerating its AI-driven innovation and premiumization in oral care while divesting non-core brands, Colgate-Palmolive could strengthen differentiation against niche rivals and maintain or grow its leading market position.
Bear case: If disruptors capture meaningful share in oral care and the recyclability litigation forces costly reforms or erodes trust, Colgate-Palmolive's narrowed focus on oral care could face sustained margin pressure and slower growth.
Colgate-Palmolive draws on its global oral care strength and the higher-margin Hill’s pet nutrition business for resilient demand. Yet analyst views indicate the upcoming quarterly results are unlikely to change the North America narrative in any real way. Does the mix of emerging-market growth and premium segments overcome the drag from developed-market categories?
Compare Colgate-Palmolive Company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside−43.1% · Bottom 25%
Profitability
Return on equity (12 months)267.4% · Top 25%
Return on assets13.1% · Top 25%
Net margin (12 months)9.7% · Above median
Operating margin (12 months)21.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)4.9% · Above median
Dividend yield (12 months)2.1% · Below median
Balance sheet
Debt / equity18.83× · Highest 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/E (12 months)38.9× · Priciest 25%
P/S (12 months)3.78× · Priciest 25%
Price / free cash flow (fiscal year)21.9× · Pricier than median
EV/EBITDA17.1× · Pricier than median
PEG1.74× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 34
FUTURE (revenue growth)25· sector 21
PAST (return on equity)100· sector 32
HEALTH (low debt)0· sector 98
DIVIDEND (yield)42· sector 53
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Colgate-Palmolive Company Fair Value". https://www.fairvalue-calculator.com/stock/CL
Frequently asked questions
Is Colgate-Palmolive Company (CL) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $56.16 versus a price of $98.69, about 43% lower (overvalued).
What is the fair value of CL?
Our model-based fair value for Colgate-Palmolive Company is $56.16 (as of Nov 6, 2026), built from audited fundamentals. The current price: $98.69.
What is the quality score of CL?
Colgate-Palmolive Company has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Colgate-Palmolive Company (CL)?
Our model-based price target is the fair value of $56.16 (as of Nov 6, 2026) from 23 valuation models. Cautious scenario $40.06, optimistic scenario $70.20. It is a calculation from audited fundamentals, not an analyst target.
What is the Colgate-Palmolive Company stock forecast for 2026?
Our models put fair value at $56.16, about 43% lower versus a price of $98.69 (overvalued). Cautious scenario $40.06, optimistic scenario $70.20. The calculation is refreshed regularly with new filings.
What is the revenue of Colgate-Palmolive Company (CL)?
Colgate-Palmolive Company reported trailing-twelve-month revenue of about $21.0B (latest available figure, as of Nov 6, 2026).
Does Colgate-Palmolive Company pay a dividend?
Colgate-Palmolive Company currently shows a dividend yield of 2.12% relative to its recent price (as of Nov 6, 2026).
What growth is priced into Colgate-Palmolive Company (CL)?
For today's price to be fair in a discounted-cash-flow model, Colgate-Palmolive Company would have to grow free cash flow by +8.1 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.4 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of CL use?
Our models discount Colgate-Palmolive Company at 8.1 %: a base by market capitalisation (large), damped by beta 0.32, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Colgate-Palmolive Company that is +8.1 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Colgate-Palmolive Company (CL) delivered so far?
Over the past 5 years revenue at Colgate-Palmolive Company grew +4.4 % a year. The price currently implies +8.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Colgate-Palmolive Company (CL) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Colgate-Palmolive Company (+8.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Colgate-Palmolive Company (CL)?
The free-cash-flow yield on the price is 4.57 %: that much free cash flow Colgate-Palmolive Company produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Colgate-Palmolive Company (CL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Colgate-Palmolive Company it is $56.16 per share (as of Nov 6, 2026), against a price of $98.69. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Colgate-Palmolive Company stock overvalued or undervalued in 2026?
As of Nov 6, 2026, CL trades above its calculated fair value: price $98.69, fair value $56.16, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CL?
No. The price is what the market pays today ($98.69); the fair value is what the company's own numbers justify ($56.16). For Colgate-Palmolive Company the two are $42.53 per share apart. That gap is exactly why we show both numbers side by side.
How much is Colgate-Palmolive Company worth?
The market values Colgate-Palmolive Company at about $79.5B (market capitalisation, as of Nov 6, 2026). Per share that is $98.69; our models calculate a fair value of $56.16 per share.
What do the bullish and bearish scenarios say about CL?
Our models span a range for Colgate-Palmolive Company: cautious scenario $40.06, base $56.16, optimistic $70.20 per share (as of Nov 6, 2026, price $98.69). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CL?
Colgate-Palmolive Company trades at a price-to-earnings ratio of 38.9 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $56.16 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 26.8 (reported for FY2025: 37.3). Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), earnings ex one-offs: 24.4. Other multiples: PEG 1.7, P/S 3.8, EV/EBITDA 17.1.
What is the PEG ratio of CL?
The PEG ratio of Colgate-Palmolive Company is 1.74 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Colgate-Palmolive Company (CL)?
Balance-sheet figures for Colgate-Palmolive Company (as of Nov 6, 2026): return on equity 267.4%, debt of 18.83 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is CL from its 52-week high?
Colgate-Palmolive Company trades at $98.69, at its 52-week high of $98.76 and 33% above the low of $74.33 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $56.16 is for.
Which stocks are comparable to Colgate-Palmolive Company?
From the same area (Consumer Defensive) we also value Kimberly-Clark Corporation, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Colgate-Palmolive Company stock attractive at the current price?
The data as of Nov 6, 2026: price $98.69, calculated fair value $56.16 (−43%), Quality Score 74/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CL calculated?
We run Colgate-Palmolive Company through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $56.16, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Colgate-Palmolive Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Colgate-Palmolive Company (CL)?
The closing price on Nov 5, 2026 was $98.69. Our model-based fair value is $56.16, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Colgate-Palmolive Company right now?
The price sits above even our optimistic bull case ($70.20). The favourable scenario is already priced in. Solid but not exceptional quality (74/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Colgate-Palmolive Company (CL) come from?
Earnings per share at Colgate-Palmolive Company grew +3.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.6 %, EBIT margin −1.7 %, tax rate +1.8 %, residual (interest, one-offs) −0.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Colgate-Palmolive Company
How large is the market capitalisation of Colgate-Palmolive Company (CL)?
The market capitalisation of Colgate-Palmolive Company is $79.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Colgate-Palmolive Company (CL)?
The price-to-sales ratio of Colgate-Palmolive Company is 3.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Colgate-Palmolive Company (CL)?
Earnings per share at Colgate-Palmolive Company are $2.54 (price ÷ EPS = P/E 38.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Colgate-Palmolive Company (CL)?
The dividend yield of Colgate-Palmolive Company is 2.1% (payout 59.1%, on adjusted earnings, reported 82.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Colgate-Palmolive Company (CL)?
The net margin of Colgate-Palmolive Company is 9.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Colgate-Palmolive Company (CL)?
The return on equity (ROE) of Colgate-Palmolive Company is 267% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Colgate-Palmolive Company (CL)?
On an EBIT basis the return on assets of Colgate-Palmolive Company is 25.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Colgate-Palmolive Company (CL)?
The operating margin of Colgate-Palmolive Company is 21.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Colgate-Palmolive Company (CL)?
Revenue at Colgate-Palmolive Company is growing +4.9% versus a year earlier (3y avg +4.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Colgate-Palmolive Company (CL)?
Earnings per share at Colgate-Palmolive Company are growing −5.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Colgate-Palmolive Company (CL) carry?
The net debt of Colgate-Palmolive Company is $6.7B (fiscal year 2025, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Colgate-Palmolive Company in the live analysis
One click puts Colgate-Palmolive Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026